

In re: Wadsworth et al.  
USSN: 10/715,976  
Filed: November 17, 2003  
Page 2

#### **I. Remarks:**

Claims 1-16 are pending in the subject application and are subject to a restriction requirement.

#### **II. Requirement for restriction under 35 U.S.C. 121**

The Office has required restriction under 35 U.S.C. § 121 to one of the following allegedly independent and distinct inventions:

I. Claims 1-8, drawn to a method of administering to an individual a nucleic acid encoding a precursor GLP-1, wherein the GLP-1 is cleaved *in vivo* which results in generation of activated GLP-1 in the individual, classifiable in class 424, subclass 93.2.

II. Claims 1-16, drawn to a method of administering to an individual a nucleic acid encoding a precursor GLP-1, wherein the GLP-1 is cleaved *ex vivo* which results in generation of activated GLP-1 in the individual, classifiable in class 424, subclass 93.21.

Applicant's undersigned agent hereby elects to prosecute the invention of Group I (Claims 1-8) drawn to a method of administering to an individual a nucleic acid encoding a precursor GLP-1, wherein the GLP-1 is cleaved *in vivo* which results in generation of activated GLP-1 in the individual.

*In re: Wadsworth et al.*  
USSN: 10/715,976  
Filed: November 17, 2003  
Page 3


### III. Summary

No fee is deemed necessary in connection with the filing of this communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 07-1074.

Respectfully submitted,

11/4/05

Date



Jennifer D. Tousignant  
Agent for Applicants  
Registration No. 54,498  
Telephone: (508) 270-2499  
Facsimile: (508) 872-5415

GENZYME CORPORATION  
15 Pleasant Street Connector  
P.O. Box 9322  
Framingham, Massachusetts 01701-9322